Trials / NCT04284293
CNS10-NPC for the Treatment of RP
Underway, not enrolling Phase 1 Gene therapy, Cell therapy
- Sponsor
- Cedars-Sinai Medical Center
- Treatment
- CNS10-NPC implantation
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 16 participants
- Started
- 2021-07-22
- Main results expected
- 2026-07
- Results posted
- Not yet
- Record last updated
- 2025-08-19
What the study is testing
The investigator is examining the safety of transplanting cells into the subretinal space of patients with Retinitis Pigmentosa (RP). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neuronal cell. The cells are called "CNS10-NPC." The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, the investigators want to learn if CNS10-NPC cells are safe to transplant into the subretinal space of people.
Where it runs
United States (1)
- Retina-Vitreous Associates Medical Group, Beverly Hills, California